Recent studies suggest that glycoprotein 130 (Gp130) receptor ligands comprise potential therapeutic targets for obesity;[12, 13] however, the role of Gp130 signaling in insulin resistance remains controversial.[14] Gp130 is the common subunit of the receptor signaling complex for the interleukin‐6 (IL‐6) family of cytokines and is ubiquitously expressed.[14] The effect of Gp130 ligands in metabolic disease is unclear and is likely to be context‐dependent, especially with respect to IL‐6. This evidence concerns the gene IL6ST and Other metabolic disease.